janus激酶抑制剂抗白细胞介素治疗在俄罗斯联邦新冠肺炎患者中的应用:药物流行病学研究

Q4 Medicine
Y. Gomon, V. V. Strizheletsky, I. G. Ivanov, A. Kolbin, A. Kalyapin, A. M. Fakhrutdinova, T. A. Usmanova
{"title":"janus激酶抑制剂抗白细胞介素治疗在俄罗斯联邦新冠肺炎患者中的应用:药物流行病学研究","authors":"Y. Gomon, V. V. Strizheletsky, I. G. Ivanov, A. Kolbin, A. Kalyapin, A. M. Fakhrutdinova, T. A. Usmanova","doi":"10.22328/2077-9828-2023-15-1-41-49","DOIUrl":null,"url":null,"abstract":"The objective of this study was to assess the volume of consumption of anti-interleukins and janus kinase inhibitors in the period 2018–2021, used as well as preventive pathogenetic therapy of COVID-19.Materials and methods. Based on actual sales data in the segments of public procurement (including regional and federal preferential drug provision) and retail sales segment in the period 2018–2021, obtained from the IQVIA database. All data was recalculated into the number of established daily doses (DDDs), with the calculation of pharmacoepidemiological indicators «Incidence of prescribing drugs», «Cumulative risk of prescribing drugs», as well as «Prescribing prevalence per year» for tocilizumab, olokizumab, levilimab, sarilumab, kanakinumab, anakinra, baricitinib, tofacitinib and upadacitinib.Results and discussion. The growth of total sales volumes was demonstrated in all market segments, but mostly in the segment of regional purchases, primarily related to the purchase of these groups of medicines for COVID-19 therapy in the period 2020–2021. It was demonstrated that the increase in the number of cases, accompanied by the expansion of prescribing preventive pathogenetic therapy, led to a twofold increase in the number of new cases of prescribing of janus kinase inhibitors and an increase in this indicator for anti-interleukins by 1.5 times, taking into account the estimated number of patients with moderate and severe COVID-19. The cumulative risk of prescribing these classes of drugs increased proportionally: for JAK inhibitors from 14 to 32%, and for anti-IL drugs from 38 to 69%. Calculations showed that the proportion of people over 18 years of age in the Russian Federation who received at least one dose of janus kinase inhibitors and anti-interleukins increased many times, in 1000 times and 500 times.Conclusions. Taking into account the expansion of the use of these groups of medicines, careful monitoring of information about their safety is required.","PeriodicalId":37381,"journal":{"name":"HIV Infection and Immunosuppressive Disorders","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of janus kinase inhibitors anti-interleukin therapy in the Russian Federation with COVID-19: pharmacoepidemiological study\",\"authors\":\"Y. Gomon, V. V. Strizheletsky, I. G. Ivanov, A. Kolbin, A. Kalyapin, A. M. Fakhrutdinova, T. A. Usmanova\",\"doi\":\"10.22328/2077-9828-2023-15-1-41-49\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The objective of this study was to assess the volume of consumption of anti-interleukins and janus kinase inhibitors in the period 2018–2021, used as well as preventive pathogenetic therapy of COVID-19.Materials and methods. Based on actual sales data in the segments of public procurement (including regional and federal preferential drug provision) and retail sales segment in the period 2018–2021, obtained from the IQVIA database. All data was recalculated into the number of established daily doses (DDDs), with the calculation of pharmacoepidemiological indicators «Incidence of prescribing drugs», «Cumulative risk of prescribing drugs», as well as «Prescribing prevalence per year» for tocilizumab, olokizumab, levilimab, sarilumab, kanakinumab, anakinra, baricitinib, tofacitinib and upadacitinib.Results and discussion. The growth of total sales volumes was demonstrated in all market segments, but mostly in the segment of regional purchases, primarily related to the purchase of these groups of medicines for COVID-19 therapy in the period 2020–2021. It was demonstrated that the increase in the number of cases, accompanied by the expansion of prescribing preventive pathogenetic therapy, led to a twofold increase in the number of new cases of prescribing of janus kinase inhibitors and an increase in this indicator for anti-interleukins by 1.5 times, taking into account the estimated number of patients with moderate and severe COVID-19. The cumulative risk of prescribing these classes of drugs increased proportionally: for JAK inhibitors from 14 to 32%, and for anti-IL drugs from 38 to 69%. Calculations showed that the proportion of people over 18 years of age in the Russian Federation who received at least one dose of janus kinase inhibitors and anti-interleukins increased many times, in 1000 times and 500 times.Conclusions. Taking into account the expansion of the use of these groups of medicines, careful monitoring of information about their safety is required.\",\"PeriodicalId\":37381,\"journal\":{\"name\":\"HIV Infection and Immunosuppressive Disorders\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Infection and Immunosuppressive Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22328/2077-9828-2023-15-1-41-49\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Infection and Immunosuppressive Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22328/2077-9828-2023-15-1-41-49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是评估2018-2021年期间抗白细胞介素和janus激酶抑制剂的消费量,以及COVID-19的预防性病理治疗。材料和方法。基于2018-2021年期间公共采购(包括地区和联邦优惠药品供应)和零售销售部分的实际销售数据,数据来自IQVIA数据库。将所有数据重新计算为确定的日剂量(DDDs),并计算tocilizumab、olokizumab、leilimab、sarilumab、kanakinumab、anakinra、baricitinib、tofacitinib和upadacitinib的药物流行病学指标“处方发生率”、“处方累积风险”以及“每年处方患病率”。结果和讨论。所有细分市场都出现了总销售额的增长,但主要是在区域采购部分,主要与2020-2021年期间购买这些用于COVID-19治疗的药物组有关。研究表明,考虑到中重度COVID-19患者的估计人数,病例数的增加,伴随着预防性病理治疗的扩大,导致janus激酶抑制剂的新病例数增加了两倍,抗白细胞介素指标增加了1.5倍。处方这类药物的累积风险按比例增加:JAK抑制剂的累积风险从14%增加到32%,抗il药物的累积风险从38%增加到69%。计算表明,俄罗斯联邦18岁以上接受至少一剂janus激酶抑制剂和抗白介素的人群比例增加了许多倍,分别为1000倍和500倍。考虑到这类药物使用的扩大,需要仔细监测有关其安全性的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The use of janus kinase inhibitors anti-interleukin therapy in the Russian Federation with COVID-19: pharmacoepidemiological study
The objective of this study was to assess the volume of consumption of anti-interleukins and janus kinase inhibitors in the period 2018–2021, used as well as preventive pathogenetic therapy of COVID-19.Materials and methods. Based on actual sales data in the segments of public procurement (including regional and federal preferential drug provision) and retail sales segment in the period 2018–2021, obtained from the IQVIA database. All data was recalculated into the number of established daily doses (DDDs), with the calculation of pharmacoepidemiological indicators «Incidence of prescribing drugs», «Cumulative risk of prescribing drugs», as well as «Prescribing prevalence per year» for tocilizumab, olokizumab, levilimab, sarilumab, kanakinumab, anakinra, baricitinib, tofacitinib and upadacitinib.Results and discussion. The growth of total sales volumes was demonstrated in all market segments, but mostly in the segment of regional purchases, primarily related to the purchase of these groups of medicines for COVID-19 therapy in the period 2020–2021. It was demonstrated that the increase in the number of cases, accompanied by the expansion of prescribing preventive pathogenetic therapy, led to a twofold increase in the number of new cases of prescribing of janus kinase inhibitors and an increase in this indicator for anti-interleukins by 1.5 times, taking into account the estimated number of patients with moderate and severe COVID-19. The cumulative risk of prescribing these classes of drugs increased proportionally: for JAK inhibitors from 14 to 32%, and for anti-IL drugs from 38 to 69%. Calculations showed that the proportion of people over 18 years of age in the Russian Federation who received at least one dose of janus kinase inhibitors and anti-interleukins increased many times, in 1000 times and 500 times.Conclusions. Taking into account the expansion of the use of these groups of medicines, careful monitoring of information about their safety is required.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HIV Infection and Immunosuppressive Disorders
HIV Infection and Immunosuppressive Disorders Medicine-Infectious Diseases
CiteScore
0.70
自引率
0.00%
发文量
37
期刊介绍: In the scientific-practical journal "HIV Infection and Immunosuppressive Disorders", published various issues of HIV medicine (epidemiology, molecular mechanisms of pathogenesis to the development of educational programs) leading scientists of Russia and countries of CIS, USA, as well as practical healthcare professionals working in research centers, research institutes, universities, clinics where done basic medical work. A special place on the pages of the publication is given to basic and clinical research, analytical reviews of contemporary and foreign reports, the provision of medical care for various diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信